Catalog No.
YHC37401
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Leu1945-Phe2222
Predicted molecular weight
34.06 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P08922
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Proto-oncogene tyrosine-protein kinase ROS, Receptor tyrosine kinase c-ros oncogene 1, c-Ros receptor tyrosine kinase, Proto-oncogene c-Ros-1, Proto-oncogene c-Ros, ROS, ROS1, MCF3
A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC., PMID:40355260
Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications., PMID:40332427
Analysis of the Relationship Between EGFR Mutations and PD-L1, ALK, and ROS1 Alterations in Patients with Non- Small-Cell Lung Cancer: The Most Extensive Study Conducted in Iran., PMID:40323238
An infant inflammatory myofibroblastoma with TFG-ROS1 fusion: a case report., PMID:40205482
Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance., PMID:40179540
Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST., PMID:40179330
Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions., PMID:40171848
Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: A systematic review., PMID:40170301
[Lung cancers with rare oncogenic drivers: RET, ROS-1, MET, HER2 and BRAF]., PMID:40155071
Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain., PMID:40154161
Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study., PMID:40142301
DNA Demethylase ROS1 Interferes with DNA Methylation and Activates Stress Response Genes in Plants Infected with Beet Severe Curly Top Virus., PMID:40141447
Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report., PMID:40120333
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting., PMID:40118657
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions., PMID:40086048
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study., PMID:40080277
Addressing challenges with Matching-Adjusted Indirect Comparisons to demonstrate the comparative effectiveness of entrectinib in metastatic ROS-1 positive Non-Small Cell Lung Cancer., PMID:40025432
Identification of Oncogenic Alterations in 124 Cases of Pediatric Papillary Thyroid Carcinoma: BEND7::ALK, DLG5::RET, and CCDC30::ROS1 Fusions Induce MAPK Pathway Activation., PMID:39982551
Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report., PMID:39907599
Rare dual MYH9-ROS1 fusion variants in a patient with lung adenocarcinoma: A case report., PMID:39854762
Assessment of Exhaled Breath Condensate for ALK, RET, ROS1, and NTRK1 Fusion Transcript Detection in NSCLC: Comparison With Tissue and Liquid Biopsy Samples., PMID:39810398
[Annual therapeutic advances in advanced non-small cell lung cancer in 2024]., PMID:39757100
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy., PMID:39748713
A new method for identifying proteins involved in DNA methylation through reverse genetics in Arabidopsis., PMID:39733860
Efficacy of Neoadjuvant Therapy for ROS1-Positive Locally-Advanced Lung Adenocarcinoma: A Case Report., PMID:39716454
Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China., PMID:39686857
Bisulfite-Free and Quantitative Detection of DNA Methylation at Single-Base Resolution by eROS1-seq., PMID:39681302
Revealing 5-(3,5-difluorobenzyl)-1H-indazole as the active pharmacophore of ALK/ROS1 dual inhibitors through theoretical calculations and biological activity evaluations., PMID:39642755
Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC., PMID:39632102
Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison., PMID:39549678
Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer., PMID:39402859
Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma., PMID:39374479
Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations., PMID:39361251
Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain., PMID:39333184
Novel therapies for pediatric low grade glioma., PMID:39324939
Additional reporting of diffuse and homogeneous ROS-1 SP384 immunoreactivity enhances prediction of ROS1 fusion-positive non-small cell lung cancer., PMID:39267255
Control of DNA demethylation by superoxide anion in plant stem cells., PMID:39266722
ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals., PMID:39260124
Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non-small cell lung cancer patients., PMID:39233657
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)., PMID:39195309
Advances and future directions in ROS1 fusion-positive lung cancer., PMID:39177972
Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study., PMID:39062837
Foritinib, a type II ROS1 inhibitor for NSCLC., PMID:39059399
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study., PMID:39059398
Top advances of the year: Targeted therapy for lung cancer., PMID:39031586
Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC., PMID:39029228
Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC., PMID:39018704
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study., PMID:39018589
Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis., PMID:39009968
ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project., PMID:39002492
For research use only. Not for human or drug use.
